

Global Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

<https://marketpublishers.com/r/G48FDB67E8DEN.html>

Date: August 2019

Pages: 86

Price: US\$ 1,799.00 (Single User License)

ID: G48FDB67E8DEN

Abstracts

High levels of pipeline activity are being observed in Neuromyelitis Optica (Devic's Syndrome) treatment during 2019. Clinical development activities are being undertaken by more than 20 companies including Abide Therapeutics Inc, Acer Therapeutics Inc, Alexion Pharmaceuticals Inc, Anvil Biosciences, Biogen Inc and others.

A Significant contribution to the Neuromyelitis Optica (Devic's Syndrome) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Neuromyelitis Optica (Devic's Syndrome) pipeline included 21 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Neuromyelitis Optica (Devic's Syndrome) condition and increased access to investments is encouraging growth of Neuromyelitis Optica (Devic's Syndrome) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Neuromyelitis Optica (Devic's Syndrome) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Neuromyelitis Optica (Devic's Syndrome) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Neuromyelitis Optica (Devic's Syndrome) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Neuromyelitis Optica (Devic's Syndrome). Further, orphan drug status, fast track designation, grants awarded and other special status for Neuromyelitis Optica (Devic's Syndrome) pipeline compounds are also included.

This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Neuromyelitis Optica (Devic's Syndrome) pipeline and formulate effective research and development strategies.

RESEARCH METHODOLOGY

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Neuromyelitis Optica (Devic's Syndrome) Pipeline candidates-

Pre-clinical Phase: Discovery, research, pre-clinical

Early Phase: Phase 1 and Phase 2 Neuromyelitis Optica (Devic's Syndrome) drugs

Late phase: Phase 3 and in-approval Neuromyelitis Optica (Devic's Syndrome) drugs

Companies involved in the Pipeline-

Company overview

Snapshot

Neuromyelitis Optica (Devic's Syndrome) therapeutic treatment activities

Details for each Neuromyelitis Optica (Devic's Syndrome) drug candidate-

Snapshot

Drug Name

Alternative Names

Company

Originator

Phase

Molecule Type

Orphan Drug Status

Drug Overview

Mechanism of Action

Current Status

Trial Details

Other details

Pre-clinical trials for each drug candidate

Clinical trials for each drug candidate

Recent Neuromyelitis Optica (Devic's Syndrome) therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news

Contents

1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2 EXECUTIVE SUMMARY

- 2.1 Neuromyelitis Optica (Devic's Syndrome)- Disease Overview
- 2.2 Neuromyelitis Optica (Devic's Syndrome)- Pipeline Snapshot
- 2.3 Neuromyelitis Optica (Devic's Syndrome)- Pipeline Drugs by Phase
- 2.4 Neuromyelitis Optica (Devic's Syndrome)- Pipeline Drugs by Company
- 2.5 Neuromyelitis Optica (Devic's Syndrome)- Pipeline Drugs by Mechanism of Action

3 COMPANY WISE PIPELINE ANALYSIS

- 3.1 Abide Therapeutics Inc Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019
- 3.2 Acer Therapeutics Inc Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019
- 3.3 Alexion Pharmaceuticals Inc Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019
- 3.4 Anvil Biosciences Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019
- 3.5 Biogen Inc Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019
- 3.6 Bionure Farma SL Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019
- 3.7 Chord Therapeutics Sarl Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019
- 3.8 Chugai Pharmaceutical Co Ltd Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019
- 3.9 Clene Nanomedicine Inc Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019
- 3.10 Endece LLC Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019
- 3.11 EnhanX Biopharm Inc Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019
- 3.12 Fundacio Clinic per a la Recerca Biomedica Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019

3.13 HanAll Biopharma Co Ltd Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019

3.14 Imstem Biotechnology Inc Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019

3.15 LFB SA Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019

3.16 Nihon Pharmaceuticals Co Ltd Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019

3.17 Orion BioScience Inc Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019

3.18 Rongchang Pharmaceutical Co Ltd Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019

3.19 Tolerion Inc Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019

3.20 Vicore Pharma AB Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019

3.21 Viela Bio Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline, H2- 2019

4 PHASE 1 PIPELINE DRUG DETAILS

4.1 Neuromyelitis Optica (Devic's Syndrome)- Phase 1 Drug Details

4.2 Neuromyelitis Optica (Devic's Syndrome)- Phase 1 Drug Overview

4.3 Neuromyelitis Optica (Devic's Syndrome)- Phase 1 Mechanism of Action

4.4 Current Status

4.5 Trial Details

5 PHASE 2 PIPELINE DRUG DETAILS

5.1 Neuromyelitis Optica (Devic's Syndrome)- Phase 2 Drug Details

5.2 Neuromyelitis Optica (Devic's Syndrome)- Phase 2 Drug Overview

5.3 Neuromyelitis Optica (Devic's Syndrome)- Phase 2 Mechanism of Action

5.4 Current Status

5.5 Trial Details

6 PHASE 3 PIPELINE DRUG DETAILS

6.1 Neuromyelitis Optica (Devic's Syndrome)- Phase 3 Drug Details

6.2 Neuromyelitis Optica (Devic's Syndrome)- Phase 3 Drug Overview

6.3 Neuromyelitis Optica (Devic's Syndrome)- Phase 3 Drug Mechanism of Action

6.4 Current Status

6.5 Trial Details

7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS

- 7.1 Neuromyelitis Optica (Devic's Syndrome)- Pre-clinical Phase Drug Details
- 7.2 Neuromyelitis Optica (Devic's Syndrome)- Pre-clinical Phase Drug Overview
- 7.3 Neuromyelitis Optica (Devic's Syndrome)- Pre-clinical Phase Drug Mechanism of Action
- 7.4 Current Status
- 7.5 Trial Details

8 RECENT NEWS AND DEVELOPMENTS

9 APPENDIX

- 9.1 About VPAResearch
- 9.2 Sources and Research Methodology

I would like to order

Product name: Global Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

Product link: <https://marketpublishers.com/r/G48FDB67E8DEN.html>

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G48FDB67E8DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

